Keryx Biopharmaceuticals, Inc. engages in the manufacture, development, and commercialization of medicines for use in treating human diseases. Its product is the Auryxia tablet. The company was founded in October 1998 and is headquartered in Boston, MA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
Frequently Asked Questions
What is Market Cap of Keryx Biopharmaceuticals, Inc.?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Keryx Biopharmaceuticals, Inc. market cap is N/A.
What is the 52-week high for Keryx Biopharmaceuticals, Inc.?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Keryx Biopharmaceuticals, Inc. 52 week high is N/A as of September 13, 2025.
What is the 52-week low for Keryx Biopharmaceuticals, Inc.?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Keryx Biopharmaceuticals, Inc. 52 week low is N/A as of September 13, 2025.
What is Keryx Biopharmaceuticals, Inc. stock price today?
Keryx Biopharmaceuticals, Inc. stock price today is $3.36.
What was Keryx Biopharmaceuticals, Inc. stock price yesterday?
Keryx Biopharmaceuticals, Inc. stock price yesterday was $3.43.
What is the PE ratio of Keryx Biopharmaceuticals, Inc.?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Keryx Biopharmaceuticals, Inc.’s P/E ratio is None.
What is the Price-to-Book ratio of Keryx Biopharmaceuticals, Inc.?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Keryx Biopharmaceuticals, Inc. P/B ratio is None.
What is Keryx Biopharmaceuticals, Inc.'s EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. Keryx Biopharmaceuticals, Inc.'s EBITDA is -5.88.
What is the 50-day moving average of Keryx Biopharmaceuticals, Inc.?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Keryx Biopharmaceuticals, Inc. 50-day moving average is N/A.
How many employess does Keryx Biopharmaceuticals, Inc. has?
